

This is a superior review article that thoroughly describes the current development status of therapeutic medicines for nonalcoholic fatty liver disease (NAFLD). Despite a considerably critical evaluation, I couldn't find any weak points in the manuscript. Congratulations! A thing that I want to comment on this review article is only the name of this liver condition. Terminology for this type of hepatic steatosis is changing to metabolic dysfunction-associated liver disease (MAFLD). I recommend use of this newly proposed name in the review article.

This manuscript reviews recent advances of the medicines for NASH in detail, especially with vast reports of clinical trials. It is praiseworthy for they to propose the significance of " real world applicability " in clinical trial. Perhaps, the future clinical trial design would pay more attention to the applicability of non-invasive endpoints.

Advances in the treatment of nonalcoholic steatohepatitis-response to reviewer's comments.

Dear Sir,

I have revised the manuscript in response to the reviewer's comments. The term nonalcoholic fatty liver disease has been substituted for metabolic dysfunction-associated fatty liver disease as requested. In addition, I have included the PMI and DOI for all the references.

Thank you,

Sandeep Mukherjee, MD